Olmesartan Medoxomil Accord

Olmesartan Medoxomil, the active ingredient in Olmesartan Medoxomil Accord, is an Angiotensin II receptor blocker (ARB) presented as a tablet for oral use. It treats hypertension in adult patients. GNH USA supplies Olmesartan Medoxomil Accord as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan Medoxomil is used to manage conditions related to the renin‑angiotensin system, primarily hypertension.

- Hypertension: lowers systolic and diastolic blood pressure and reduces cardiovascular risk. - Heart failure: may be added to standard therapy to improve afterload reduction. - Diabetic nephropathy: helps slow progression of renal impairment in patients with type 2 diabetes.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate intensity. - Fatigue: feeling unusually tired. - Nausea: upset stomach or urge to vomit. - Diarrhea: loose stools. - Cough: dry, non‑productive cough.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat requiring emergency care. - Hyperkalemia: elevated blood potassium that can affect heart rhythm. - Acute renal failure: sudden loss of kidney function. - Severe hypotension: dangerously low blood pressure, especially after dose escalation. - Hepatic injury: abnormal liver enzymes or jaundice. - Myocardial infarction: rare reports of heart attack in susceptible patients.

Before initiating therapy, consider the following precautions: - Blood pressure monitoring: check regularly to avoid excessive hypotension. - Renal function assessment: evaluate serum creatinine and eGFR, especially in patients with chronic kidney disease. - Serum potassium: monitor for hyperkalemia, particularly when combined with potassium‑sparing agents. - Hepatic impairment: use with caution in severe liver disease. - Pregnancy: avoid use during pregnancy as safety has not been established. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Olmesartan Medoxomil can interact with several drug classes.

Major Interactions (Avoid): - ACE inhibitors: concurrent use may increase risk of angioedema and hyperkalemia. - Aliskiren (in diabetes): combined therapy can cause renal dysfunction and hyperkalemia. - Potassium‑sparing diuretics: may lead to dangerous elevations in serum potassium. - NSAIDs: can blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely):\n- Thiazide diuretics: additive blood‑pressure lowering effect; monitor for hypotension. - Lithium: may increase lithium concentrations; check lithium levels. - CYP450 inhibitors/inducers: may modestly affect olmesartan plasma levels; adjust monitoring as needed.